Table 2 Baseline characteristics of TCGA patients
From: CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer
Characteristics | Low expression of CPA4 | High expression of CPA4 | P value |
|---|---|---|---|
n | 184 | 155 | Â |
Clinical stage, n (%) | Â | Â | 0.178 |
 Stage I | 125 (36.9%) | 89 (26.3%) |  |
 Stage II | 12 (3.5%) | 18 (5.3%) |  |
 Stage III | 38 (11.2%) | 40 (11.8%) |  |
 Stage IV | 9 (2.7%) | 8 (2.4%) |  |
Primary therapy outcome, n (%)a | Â | Â | 0.345 |
 PD&SD&PR | 17 (5%) | 10 (2.9%) |  |
 CR | 167 (49.3%) | 145 (42.8%) |  |
Age, n (%) | Â | Â | 0.018 |
  <  = 60 | 59 (17.4%) | 69 (20.4%) |  |
  > 60 | 125 (36.9%) | 86 (25.4%) |  |
Histological type, n (%) | Â | Â | 0.153 |
 Endometrioid | 145 (42.8%) | 114 (33.6%) |  |
 Serous | 34 (10%) | 30 (8.8%) |  |
 Mixed | 5 (1.5%) | 11 (3.2%) |  |
Histologic grade, n (%) | Â | Â | 0.014 |
 G1 | 53 (15.6%) | 24 (7.1%) |  |
 G2 | 40 (11.8%) | 41 (12.1%) |  |
 G3 | 91 (26.8%) | 90 (26.5%) |  |
Tumor invasion (%), n (%) | Â | Â | 0.497 |
  < 50 | 110 (32.4%) | 87 (25.7%) |  |
  >  = 50 | 74 (21.8%) | 68 (20.1%) |  |
Menopause status, n (%) | Â | Â | 0.349 |
 Pre | 17 (5%) | 8 (2.4%) |  |
 Peri | 7 (2.1%) | 7 (2.1%) |  |
 Post | 160 (47.2%) | 140 (41.3%) |  |
Diabetes, n (%) | Â | Â | 0.595 |
 No | 133 (39.2%) | 116 (34.2%) |  |
 Yes | 51 (15%) | 39 (11.5%) |  |
BMI, n (%) | Â | Â | 0.260 |
  <  = 30 | 65 (19.2%) | 64 (18.9%) |  |
  > 30 | 119 (35.1%) | 91 (26.8%) |  |